Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 5 Sub-analysis for prehypertension and hypertension by duration of OC use, compared to other contraceptive users

From: The use of oral contraceptives and the risks of developing prehypertension and hypertension in women of reproductive age: findings from a population-based survey in Indonesia

 

IFLS-5 (2014–2015)

Normal

Prehypertension

p-value

Hypertension

p-value

Non-user

Reference

0–12 month

Crude OR (95% CI)

Ref

1.13 (0.75–1.70)

0.569

1.58 (1.12–2.22)

0.008*

Adjusted ORa (95% CI)

Ref

1.18 (0.77–1.80)

0.440

1.81 (1.26–2.61)

0.001*

12–24 month

 

Crude OR (95% CI)

Ref

0.94 (0.37–2.40)

0.893

1.76 (0.89–3.49)

0.104

Adjusted OR a(95% CI)

Ref

0.91 (0.35–2.36)

0.844

1.97 (0.95–4.09)

0.068

> 24 month

     

Crude OR (95% CI)

Ref

1.35 (0.97–1.88)

0.080

2.51 (1.95–3.2)

< 0.001*

Adjusted ORa (95% CI)

Ref

1.22 (0.86–1.72)

0.260

2.14 (1.62–2.81)

< 0.001*

  1. OC: oral contraceptive
  2. aadjusted to age, residential location, level of education, employment status, obesity, physical activity levels, dietary habits, diabetes mellitus, CVDs, and dyslipidemia
  3. ∗p < 0.05 at the 5% level of significance
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us